Dual Targeting of DNA and EGFR by ZYH005 Induces DNA Damage and

Mitotic Catastrophe in Glioblastoma

Jianzheng Huang[1], Zijun Zhang[1], Yang Xiao[1], Ziming Zhao[1], Zengwei Luo[1], Junjun

Liu[1], Suitian Lai[1], Chao Song[2], Shouchang Feng[3], Suojun Zhang[3], Xingjiang Yu[2],

Qingyi Tong[1*], Yonghui Zhang[1*]

[1]Department of Hubei Key Laboratory of Natural Medicinal Chemistry and Resource

Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of

Science and Technology, Wuhan, 430030, China;

[2]Department of Histology and Embryology, School of Basic Medicine, Tongji

Medical College, Huazhong University of Science and Technology, Wuhan, China;

[3]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong

University of Science and Technology, Wuhan, China.

Corresponding Author: Yonghui Zhang, (zhangyh@mails.tjmu.edu.cn.); Qingyi Tong,

(qytong@hust.edu.cn.);

Abstract

Background: Glioblastoma (GBM) is an aggressive, therapy-resistant brain tumor

with limited treatment options. Epidermal growth factor receptor (EGFR) is

frequently amplified and activated in GBM, driving tumorigenesis through

pro-oncogenic signaling and coordination of nuclear DNA repair. This study examines

the anti-GBM efficacy and mechanism of ZYH005 (Z5), a brain-penetrant DNA

intercalator exhibiting low systemic toxicity.

Methods: Antitumor efficacy of Z5 was determined with GBM cell lines and

patient-derived glioblastoma stem cells (GSCs) in vitro and in vivo. Target

identification and mechanistic validation were performed using DNA microarray,

surface plasmon resonance, immunoblot and siRNA silencing. The EGFR-WEE1

correlation was analyzed via public databases and confirmed by

coimmunoprecipitation.

Results: Z5 significantly inhibits the proliferation of GBM cell lines and

patient-derived GSCs, effectively suppresses tumor growth in orthotopic

GSC-induced mouse models, prolongs survival, and shows no obvious toxicity.

Mechanistically, Z5 exerts potent anti-GBM activity through a dual mechanism: DNA

intercalation-induced damage and targeted inhibition of EGFR. By specifically

inhibiting EGFR at E762, Z5 not only enhances DNA damage by suppressing the

DNA damage response in the nucleus but also disrupts the interaction between nuclear

EGFR and WEE1, leading to impaired WEE1/CDC2 signaling and G2/M checkpoint

failure. Extranuclearly, Z5 further enhances its anti-GBM efficacy by inhibiting the

canonical EGFR downstream pathways, mTOR and ERK. Together, these molecular

events promote cell cycle arrest and mitotic catastrophe in GBM cells.

Conclusion: Z5 emerges as a promising brain-penetrant clinical candidate for

treating GBM. It acts through a dual mechanism that synergistically targets both DNA

and EGFR, inducing mitotic catastrophe while demonstrating a favorable safety

profile. These compelling findings provide a strong rationale for advancing Z5 toward

clinical translation, offering a novel therapeutic strategy for GBM patients.

Keywords: Glioblastoma; DNA damage; EGFR-WEE1 axis; mitotic catastrophe

1. Background

Glioblastoma (GBM) stands as the most invasive and deadly primary brain tumor

among adults[1]. It constitutes around 49% of all malignant central nervous system

tumors. In high-income countries, its annual incidence is 3-7 cases per 100,000

individuals[2, 3]. The treatment of GBM adopts a multimodal strategy, integrating

surgery, radiotherapy, and temozolomide (TMZ)-based chemotherapy. However, the

median survival time for GBM patients is a mere 12-16 months, and the 5-year

survival rate remains below 5%[2, 3]. This persistent therapeutic impasse underscores

the critical need for paradigm-shifting treatment strategies in neuro-oncology.

Epidermal growth factor receptor (EGFR) and its constitutively active mutant

EGFRvIII are well-established oncogenic drivers in GBM, with gene amplification

occurring in over 50% of cases, particularly in the classical subtype[4]. Beyond

activating canonical signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, and

JAK/STAT—which collectively promote tumor proliferation, survival, and

invasion—EGFR also translocates to the nucleus, where it directly facilitates DNA

repair. There, it interacts with DNA-PKcs to enhance its phosphorylation, bolstering

non-homologous end joining (NHEJ)[5, 6]. Furthermore, through the

RAS/RAF/MEK/ERK and PI3K/AKT cascades, EGFR modulates the expression of

DNA repair factors such as XRCC1 and RAD51, thereby enhancing DNA damage

response (DDR) homeostasis and aiding tumor cells in evading genotoxic stress[7, 8].

This central role of EGFR in coordinating DDR underlies why its pharmacological

inhibition not only disrupts DNA repair mechanisms but also sensitizes GBM cells to

radiotherapy and DNA-damaging agents[9, 10]. Together, these multifaceted

functions solidify EGFR's position as a cornerstone therapeutic target in GBM.

Tyrosine kinase inhibitors (TKIs) show inhibitory activity against EGFR, their

monotherapy efficacy in GBM is limited due to tumor heterogeneity, compensatory

signaling pathways, and the blood–brain barrier (BBB)[11]. Accordingly,

combination strategies—particularly pairing EGFR-TKIs with MEK/PI3K inhibitors

or DNA-damaging agents (e.g., temozolomide, radiotherapy)—are required to achieve

superior therapeutic outcomes. Preclinical studies further demonstrate that timed

EGFR-TKI administration (≥4 hours before DNA damage induction) potentiates

tumor cell killing by prolonging DDR pathway disruption[12, 13]. However,

combination regimens are often limited by increased toxicity, complex

pharmacokinetics, and challenges in optimizing drug sequencing and dosing. These

limitations have spurred growing interest in dual-targeting strategies that

simultaneously disrupt EGFR signaling and induce DNA damage. A representative

example is ZR2002, a small-molecule agent designed to covalently modify DNA

bases via a haloalkyl arm, thereby compromising DNA integrity while concurrently

inhibiting EGFR activity. ZR2002 exhibits potent submicromolar anti-proliferative

activity even against temozolomide-resistant GSCs [14], highlighting the promise of

co-targeting EGFR and DNA.

Phenanthridinone represents an important class of heterocyclic frameworks

frequently found in bioactive alkaloids[15] and serves as a core structure with

significant potential in antitumor drug discovery[16, 17]. Previously, we synthesized a

series of novel phenanthridinone derivatives and identified a crinasiadine-type

derivative, ZYH005 (Z5), as the most potent compound, exhibiting even stronger

anticancer activity than the well-known phenanthridinone alkaloid narciclasine. In

tumor-bearing mouse models, at safe doses, narciclasine significantly inhibited the

growth of primary GBM, brain-metastatic melanoma, and lung cancer, but not that of

other cancer types[18, 19]. Its relatively high lipophilicity, which facilitates BBB

penetration, makes narciclasine a promising candidate for GBM therapy[20]. Another

notable phenanthridinone alkaloid, lycorine, has been reported to induce apoptosis in

GBM cells through EGFR inhibition and demonstrates efficacy in patient-derived

xenograft models[21]. Similarly, narciclasine suppresses gastric cancer cell

proliferation via modulation of the AKT/mTOR pathway, which is linked to EGFR

signaling[22]. These findings underscore the therapeutic potential of phenanthridinone

alkaloids that target EGFR-related mechanisms[22]. Structurally, Z5 possesses fewer

hydrophilic hydroxyl groups than narciclasine, suggesting higher theoretical

lipophilicity. Consistent with this, we demonstrated that Z5 exhibits superior BBB

permeability in mice compared to narciclasine (Supplementary Figure 1A–D).

Nevertheless, the anti-GBM efficacy and molecular mechanisms of this novel and

more potent phenanthridinone derivatives—particularly their potential interaction

with EGFR signaling—remain to be elucidated.

In the present study, we clearly demonstrated that Z5 exerts a significant

inhibitory effect on GBM cells and patient-derived glioblastoma stem cells (GSCs) in

vitro and in vivo. We confirmed for the first time that Z5 exerts anti-GBM effects

through a unique dual-mechanism approach, simultaneously acting as a DNA

intercalator and a selective EGFR inhibitor. These findings not only provide a

mechanistic foundation for the development of Z5 as a lead compound but also

highlight a novel therapeutic hope for GBM, demonstrating compelling potential

against this aggressive malignancy and warranting further investigation.

2. Materials and Methods

2.1 Compounds and cell lines

Z5 was synthesized in our laboratory, and its synthesis process has been described

previously[17]. The U87-MG (RRID: CVCL_0022), U251-MG (RRID: CVCL_0021)

and HEK293T (RRID: CVCL_0063) cell lines were purchased from Procell Life

Science & Technology. GSCs (T3359) were provided by Dr. Shideng Bao and Dr.

Jeremy Rich[23]. U87-MG, U251-MG and HEK293T cells were cultured in DMEM

(Pricella, Wuhan, China) supplemented with 10% fetal bovine serum (FBS) and 1%

penicillin/streptomycin. GSCs were cultured in a serum-free system containing

Neurobasal A basal medium supplemented with B-27 supplement minus vitamin

A, L-glutamine, sodium pyruvate, 20 ng/ml recombinant epidermal growth factor, and

20 ng/ml basic fibroblast growth factor. The cell culture, cryopreservation, and

thawing procedures were all meticulously conducted in strict accordance with

standard operating procedures (SOPs). Short tandem repeat (STR) profiling and

contamination assessment of the cell lines were performed every six months. The

results verified the authenticity of the cell lines and confirmed their

contamination-free status.

2.2 DNA Microarrays and Gene Set Enrichment Analysis (GSEA)

Total RNA was extracted from U87-MG cells using TRIzol reagent (Cat# 15596-018,

Life Technologies, Carlsbad, CA, US). RNA purification was performed using the

NucleoSpin RNA Clean-up XS kit (Cat#740903, MN, Germany) and the RNase-Free

DNase Set (Cat#79254, QIAGEN, GmBH, Germany). According to the Affymetrix

technical manual, the double-stranded cDNA was hybridized with biotin-labeled

fragmented cRNA. Microarray experiments were performed using Affymetrix chips

by Shanghai Biotechnology Corporation. The raw data were normalized via the

expression console algorithm in Command Console Software 4.0 (Affymetrix, Santa

Clara, CA, US). Differential expression analysis was conducted via the affy package

in R. Genes with an absolute log2-fold change >1 and a P value <0.05 were

considered differentially expressed. The microarray data for U87-MG cells have been

submitted to the NGDC/OMIX under accession number OMIX008765. Significantly

differentially expressed genes ($|Log2FC| \geq 1$, FDR $\leq$ 0.05) are listed in

Supplementary Table 1. All genes identified through DNA microarray analysis were

imported into GSEA software for further analysis and visualization.

2.4 Molecular Docking of Z5 with the EGFR Kinase Domain

For our molecular docking experiments, we utilized the crystal structure of EGFR

(PDB ID 7KXZ)[24]. This structure was preprocessed via the PDB2PQR program[25]

to determine the protonation state of titratable residues at pH=7 and subsequently

converted to pdbqt format via the prepare_receptor4.py script from

AutoDockTools[26]. Next, we prepared Z5 by converting the compounds to pdbqt

format (pH 7.0) via Open Babel. Molecular docking scores were used as indicators of

the predicted binding affinity.

2.5 Limited Proteolysis–Mass Spectrometry (LiP-MS)

LiP-MS was performed as previously published[27]. A detailed description is

provided in the **Supplementary Material**.

2.6 Tissue Microarray (TMA) and Immunohistochemistry (IHC)

TMAs were obtained from Wuhan Powerful Biology Company. The use of human

tissues in this study was approved by the Ethics Committee of Tongji Hospital of

Tongji Medical College of Huazhong University of Science and Technology (Serial

number: 2021-lEC-A244). TMA sections were deparaffinized and subjected to antigen

retrieval prior to immunostaining. WEE1 antibody (Cell Signaling Technology, 1:200

dilution) was used to detect the protein in the GBM tissue samples.

IHC for in situ transplanted mouse brain tissues was carried out via the same protocol

as described above. WEE1 antibody (Cell Signaling Technology, 1:200 dilution) and

EGFR antibody (Proteintech, 1:100 dilution) were used to detect the protein.

2.7 Orthotopic transplantation mouse model

Experimental BALB/c nude mice were purchased from Beijing Vital River Laboratory

Animal Technology Co., Ltd. (Beijing, China) and kept at the Experimental Animal

Center of Tongji Medical College, Huazhong University of Science and Technology,

Wuhan, China. All the mice were anesthetized with phenobarbital sodium before

surgery. One week after GSCs (2×10^4 cells/mouse) were implanted in the right frontal

lobe of 4-week-old mice, 15 mice were randomly divided into three groups: the

untreated (NT), Z5 low-dose (10 mg/kg) and Z5 high-dose (20 mg/kg) groups. The

mice received either solvent (5% DMSO, 20% castor oil, and 75% saline) or varying

doses of the drug by oral gavage daily for 7 weeks. When the NT group showed the

first manifestation of obvious neurological signs, one mouse from each of the

remaining two groups was evaluated for drug efficacy. The remaining 12 mice were

used for survival studies.

2.8 Statistical analysis

Statistical analysis was performed via GraphPad Prism 9.0 software. The data are

expressed as the means ± SDs. We used unpaired t tests for statistical analysis

between 2 groups and one-way ANOVA for multiple comparisons. All the

experiments were repeated more than 3 times. We considered a p value less than 0.05

to indicate statistical significance.

3. Results

3.1 Z5 suppresses proliferation and inhibits EGFR mediated signaling in GBM

cell lines

Using two representative GBM cell lines, U87-MG and U251-MG, we demonstrated

that Z5 potently inhibits GBM cell proliferation in a time- and

concentration-dependent manner. After 72 hours of treatment, the IC_{50} values were

0.114 ± 0.016 μM for U87-MG and 0.147 ± 0.049 μM for U251-MG cells (Figure 1A).

Notably, treated with 0.2 μM Z5 for 48 h resulted in approximately 50% inhibition of

cell proliferation in both cell lines, whereas the IC_{50} value of lycorine in U251-MG

cells was 10 μM under the same conditions[21], indicating that Z5 exhibits superior

antiproliferative activity to lycorine in GBM cells.

Furthermore, Z5 significantly suppressed colony formation in both cell lines

(Figure 1B). The EdU incorporation assay further demonstrated marked inhibition of

DNA synthesis following Z5 treatment, which is key characteristics associated with

suppressed cell proliferation (Figure 1C–D). Consistent with its antiproliferative

effects and similar to the activity of lycorine[21], treatment with Z5 also significantly

suppressed the EGFR signaling pathway, as demonstrated by reduced phosphorylation

levels of key biomarkers including EGFR (p-EGFR), ERK (p-ERK), and mTOR

(p-mTOR) (Figure 1E).

Figure 1 Z5 suppresses proliferation and blocks EGFR-mediated signaling in

GBM cell lines. (A) Cell viability of GBM cell lines was assessed by CCK-8 assays

after treatment with Z5 for 24, 48, and 72 hours. (B) The inhibitory effect of Z5 was

evaluated using the colony formation assay. (C) Fluorescence images showing EdU

incorporation in GBM cells under various treatment conditions (red: EdU staining;

blue: Hoechst staining). (D) Quantification of EdU-positive cells in each group. The

data are presented as the means ± SDs; n=3, compared with the DMSO group. (E) The

expression levels of EGFR, p-EGFR, ERK, p-ERK, mTOR and p-mTOR were

analyzed by immunoblotting after Z5 treatment.

3.2 Z5 suppresses GBM partly through selective targeting of EGFR

To determine whether Z5 directly targets EGFR, we performed a series of

biochemical assays. Cellular thermal shift assay (CETSA) demonstrated that Z5

enhanced the thermal stability of EGFR in both U87-MG and U251-MG cell lines

(Figure 2A), whereas drug affinity responsive target stability (DARTS) assay also

revealed that Z5 protected EGFR from proteolytic degradation (Figure 2B). Most

conclusively, surface plasmon resonance (SPR) experiments confirmed direct binding

between Z5 and the EGFR kinase domain, with a dissociation constant (KD) of 19.6

μM (Figure 2C).

To confirm the interaction between Z5 and EGFR, we examined how EGFR

silencing influences the antiproliferative effects induced by Z5. The knockdown

efficiency of EGFR-targeting siRNAs was first evaluated in GBM cell lines. Based on

its superior performance, siEGFR-1261 was selected for further experiments (Figure

2D). Our results demonstrate that EGFR knockdown attenuated—but did not

abolish—the anti-proliferative effect of Z5, as evidenced by CCK-8 and EdU assays

(Figure 2E–F). Together, these findings establish that Z5 targets EGFR and that its

anti-GBM efficacy is largely mediated through this interaction.

Figure 2 Z5 suppresses GBM partly through selective targeting of EGFR. (A)

CETSA assay was performed to assess target engagement of Z5 (0.1 mM) with EGFR

in cells. EGFR expression was detected by immunoblotting. (B) DARTS assay was

used to evaluate the direct binding of Z5 to EGFR at varying concentrations. EGFR

expression was detected by immunoblotting. (C) The direct binding affinity between

Z5 and the recombinant EGFR kinase domain protein was analyzed by SPR. (D)

EGFR silencing efficiency was evaluated by immunoblot analysis after transfection

with EGFR siRNA. (E) Growth curves of NC and si-EGFR-1261 GBM cell lines

were measured following treatment with Z5 for 48 h. (F) The anti-proliferative effect

of Z5 in NC and si-EGFR-1261 GBM cells was assessed by EdU assay.

3.3 Z5 binds to the E762 residue of EGFR

Having established that Z5 directly targets EGFR, we further investigated the

structural basis of this interaction. Molecular docking simulations were performed

targeting the ATP-binding pocket of the EGFR kinase domain (PDB: 7KXZ). Detailed

analysis of the binding mode revealed key molecular interactions between Z5 and

EGFR: (1) extensive hydrophobic contacts with residues V702, L820, and L694,

stabilizing its position within the ATP-binding pocket; and (2) two critical hydrogen

bonds formed with K721 and T766, which likely contribute to its high binding affinity

(Figure 3A).

To experimentally validate these computational predictions, we employed limited

proteolysis☐mass spectrometry (LiP☐MS), a label-free proteomics approach, to map

potential binding sites of Z5 within the EGFR kinase domain. The LiP-MS analysis

identified several peptide segments that are likely involved in Z5 binding (Figure

3B-C). Although the residues K721 and T766—previously implicated in hydrogen

bonding by docking studies—were not directly detected by LiP–MS, we observed that

K721 forms a hydrogen bond with E738. This interaction may stabilize K721 and

thereby indirectly support its hydrogen bonding with Z5. Based on these integrated

findings, we propose E738 (corresponding to E762 in UniProt entry P00533-1) as a

critical binding residue for Z5. To functionally validate the significance of E762, we

established an ectopic expression system in HEK293T cells transfected with empty

vector, wild-type (WT) EGFR, or the E762V mutant EGFR (Figure 3D).

Dose response experiments using CCK-8 assay revealed that the antiproliferative

effect of Z5 plateaued at concentrations above 0.1 μM, with residual cell viability

stabilizing around 75% (Figure 3E). Based on these observations, we selected 0.2 μM

Z5 for subsequent experiments to ensure detectable antiproliferative effects while

avoiding complete cytotoxicity. Functional validation using both CCK-8 and EdU

assays demonstrated that the E762V mutation significantly compromised the

antiproliferative effect of Z5 (Figure 3F-G). Compared with cells expressing

WT-EGFR, those carrying the E762V mutation exhibited markedly higher cell

viability and enhanced proliferative capacity after Z5 treatment. These results confirm

that E762 serves as a critical binding residue for Z5 on EGFR and is essential for

mediating its antiproliferative activity.

Figure 3 Z5 binds to the E762 residue of EGFR. (A) Predicted binding mode of Z5 within the EGFR kinase domain. (B) Red regions represent peptides with increased proteolytic susceptibility upon Z5 treatment. The selection criteria were as follows: log2(fold change) > 2 and -log10(P value) > 2. (C) Scatter plot displaying changes in peptide abundance from Lip-MS analysis. Each point represents a peptide, with fold-change differences shown between Z5-treated and control samples. (D) Expression of Flag-tagged EGFR and total EGFR in HEK293T cells was analyzed by immunoblotting after transfection with different plasmids. (E) Growth curves of HEK293T cells following treatment with Z5 for 48 h. (F) Growth curves of HEK293T cells transfected with empty vector (vehicle), wild-type (WT) EGFR, or the E762V

mutant EGFR, following treatment with Z5 for 48 h. (G) Fluorescence images of

proliferating GBM cell lines under various treatment conditions (green: EdU staining;

blue: Hoechst staining).

3.4 Z5 induces DNA damage through DNA intercalation and EGFR inhibition

To gain deeper insights into the molecular mechanisms underlying Z5-mediated

EGFR inhibition, we conducted a comprehensive microarray analysis in U87-MG

cells treated with Z5. The analysis identified a total of 1,970 differentially expressed

genes (DEGs), among which 188 were upregulated and 1,782 were downregulated

(Supplementary Figure 2A). Notably, PRIM1, PRKDC, and MKI67 exhibited the

most pronounced downregulation (Supplementary Figures 2B–C).

We next interrogated the microarray data using the Connectivity Map (CMap)

database. Querying CMap with a signature comprising the top 66 upregulated and top

150 downregulated genes from our microarray data yielded positive connectivity

scores for multiple compounds. We categorized the data by cell type and selected only

samples treated with inhibitor perturbations to identify the top ten most effective

inhibitors in each cell type. The results showed that EGFR inhibitors appeared most

frequently, indicating that the transcriptional impact of Z5 treatment resembles that of

multiple known EGFR inhibitors (Figure 4A). This conclusion was further supported

by GSEA analysis: Z5 significantly suppressed the activation of ERBB signaling,

PI3K/AKT/mTOR pathway, and mTORC1 activity in cells (Figure 4B)—all of which

are established pharmacological effects of EGFR inhibition. Together, these data

demonstrate that the effect of Z5 on GBM cells is strongly associated with EGFR

suppression, further confirming that Z5 acts as a targeted EGFR inhibitor.

Cellular Component (CC) enrichment analysis from GO and GSEA further

revealed significant enrichment of dysregulated genes involved in nuclear

compartments, replication forks, and chromosomal regions following Z5 treatment

(Figure 4C–D), consistent with its DNA intercalating properties. In line with these

findings, Z5 treatment induced significant DNA damage in GBM cells, as evidenced

by increased APE1-mediated cleavage events—detected using a dual-amplification

fluorescent biosensor[28]—and elevated γH2AX foci indicating double-strand breaks

(Figure 4E–F). These findings suggest that the nucleus serves as a primary site for

Z5's mechanism of action.

It is well-established that nuclear EGFR plays a critical role in the DDR, and that

EGFR inhibition impairs DDR, resulting in accumulation of DNA damage. In line

with this, GSEA showed significant downregulation of DNA repair pathways after Z5

treatment (Figure 4G, Supplementary Figure 2D), confirming that Z5 acts as an EGFR

inhibitor to suppress the DDR. To further examine whether EGFR contributes to

Z5-induced DNA damage, we knocked down EGFR using siEGFR-1261. First, we

found that EGFR knockdown alone—despite its potential to suppress DDR—did not

induce DNA damage in the absence of Z5 treatment. Second, EGFR knockdown

reduced Z5-induced DNA damage compared to wild-type cells (Figure 4E), indicating

that EGFR plays a functional role in Z5-mediated DNA damage. Specifically, EGFR

inhibition by Z5 acts synergistically to amplify DNA damage initiated through its

primary mechanism of DNA intercalation. Together, these results demonstrate that Z5

induces DNA damage via a dual mechanism involving both DNA intercalation and

EGFR inhibition.

348
Figure 4 Z5 induces DNA damage through DNA intercalation and EGFR

inhibition. (A) From CMAP data, the top 10 compounds positively correlated with

microarray profiles were selected per cell line. Compound descriptions were

statistically analyzed and ranked by term frequency. (B) GSEA of the ERBB signaling

pathway, PI3K/AKT/mTOR signaling and mTORC1 signaling. (C) Top 5 enriched

GO terms among downregulated genes in U87-MG cells. (D) GSEA analysis of all

genes identified by the U87-MG microarray. Cen: chromosome centromeric region;

CCen: condensed chromosome centromeric region. (E) EGFR and γ-H2AX

expression in NC and si-EGFR-1261 GBM cells was analyzed by immunoblotting

after 48 h Z5 treatment. (F) Increased APE1-accessible DNA damage in Z5 treated

cells. (G) GSEA of the DNA repair and double strand break repair.

3.5 Z5 induces G2/M arrest and WEE1-mediated mitosis catastrophe through EGFR inhibition

Following DNA damage, cells typically initiate cell cycle arrest to allow time for repair. Consistent with this mechanism, KEGG and GO analyses indicated that Z5 predominantly affects pathways related to cell cycle regulation and mitotic progression (Figure 5A). Subsequent GSEA using the GO-BP, HALLMARK, and KEGG databases further underscored significant enrichment of terms associated with G2/M checkpoint signaling, G2/M phase transition, cell cycle control, and mitotic spindle assembly (Figure 5B, Supplementary Figure 2E). These findings suggest that Z5 disrupts the tightly regulated G2/M transition process. Consistent with these findings, we observed a robust arrest in the G2/M phase by flow cytometry (Figure 5C). Notably, Z5 treatment markedly elevated the populations of PHH3-positive and polyploid cells (Figure 5D), a hallmark of mitotic catastrophe that is consistent with checkpoint failure. In addition, we found that EGFR knockdown completely abolished Z5-induced G2/M arrest, demonstrating that Z5-mediated cell cycle blockade is strictly dependent on EGFR inhibition (Figure 5E). To elucidate how Z5 disrupts the G2/M checkpoint through EGFR, we analyzed DEGs from microarray data. Among key regulators of the G2/M checkpoint, WEE1 showed the most pronounced downregulation (67%), while CDC2 (also known as CDK1)—which is phosphorylated by WEE1 to regulate mitotic entry—was also substantially reduced (55%) (Supplementary Table 1), suggesting transcriptional disruption of the WEE1-mediated checkpoint by Z5. Corroborating these findings, immunoblot

analysis showed decreased phosphorylation of WEE1 and CDC2, along with upregulated PHH3 expression following Z5 treatment (Figure 5F). Furthermore, immunofluorescence (IF) assays unveiled hallmark morphological features of mitotic catastrophe, such as chromosomal mis-segregation, multipolar spindle formation, and micronucleation (Figure 5G). Collectively, these results demonstrated that Z5 induces G2/M arrest and mitotic catastrophe through EGFR-mediated inhibition of the WEE1 checkpoint.

Figure 5 Z5 induces G2/M arrest and mitotic catastrophe in GBM cells. (A)

KEGG pathway enrichment analysis of microarray data from GBM cells. (B) GSEA

of the G2M checkpoint, cell cycle and cell cycle G2/M phase transition pathways. (C)

Cell cycle distribution in GBM cell lines was analyzed by flow cytometry after 24 h

Z5 treatment. (D) Representative flow cytometric analysis of PHH3+ and DNA

contents > 4n cells. (E) Cell cycle profiles of NC and si-EGFR GBM cells were

assessed by flow cytometry after 24 h Z5 treatment. (F) Expression of WEE1,

p-WEE1, PHH3, CDC2, and p-CDC2 was analyzed by immunoblotting after 48 h

treatment with increasing concentrations of Z5. (G) IF staining was performed with

anti-tubulin (red) and anti-PHH3 (green) antibodies in U87-MG and U251-MG cells

treated with DMSO or Z5.

3.6 Z5 targets nuclear EGFR to disrupt the EGFR-WEE1 axis

To investigate whether the anti-GBM efficacy of Z5 involves functional crosstalk

between EGFR and WEE1, we first analyzed their correlation in glioma

transcriptomes. Data from the Chinese Glioma Genome Atlas (CGGA) revealed a

significant positive correlation between EGFR and WEE1 mRNA expression

(Pearson's R = 0.38; Figure 6A). To determine whether this co-expression reflects

direct molecular interaction, we performed SPR analysis, which demonstrated

high-affinity binding between the kinase domains of EGFR and WEE1 with an

equilibrium dissociation constant (KD) of 17.3 nM (Figure 6B). This interaction was

further confirmed by co-immunoprecipitation (Co-IP) in GBM cells. Importantly, Z5

treatment significantly disrupted the EGFR–WEE1 complex, as shown by reduced

Co-IP of both proteins (Figure 6C; Supplementary Figure 3A).

Next, we performed genetic and pharmacological perturbations in U87-MG

cells to dissect the functional relationship between EGFR and WEE1. Knockdown of

WEE1 did not affect EGFR expression or phosphorylation. In contrast, EGFR

knockdown significantly reduced both total WEE1 and phospho-WEE1 levels,

establishing EGFR as an upstream regulator of WEE1 (Supplementary Figure 3B).

Consistent with these findings, the WEE1 inhibitor MK1775 had minimal impact on

EGFR signaling, whereas the EGFR inhibitor AZD9291 strongly suppressed both

p-WEE1 and p-CDC2. These results confirm a unidirectional regulatory axis from

EGFR to WEE1 (Supplementary Figure 3C). Building on this established EGFR to

WEE1 signaling relationship, we further investigated whether Z5 exerts its effects

through direct interaction with EGFR. In 293T cells expressing the E762V mutant

EGFR, Z5-induced downregulation of p-WEE1 and p-CDC2 was markedly

attenuated compared to wild-type controls (Figure 6D). This indicates that Z5 targets

EGFR via the E762 residue to inhibit its activity and disrupt the EGFR–WEE1

regulatory axis.

Since EGFR undergoes nucleocytoplasmic shuttling and WEE1 is

predominantly nuclear, we hypothesized that their interaction is nuclear-specific. To

test this, we assessed their co-localization. In control (DMSO-treated) cells, both IF

and cellular fractionation confirmed substantial nuclear co-localization of EGFR and

WEE1. Z5 treatment, however, disrupted this co-localization, resulting in the

dissociation of both proteins and their accumulation in the cytoplasm (Figure 6E–F;

Supplementary Figure 3D).

We next investigated whether the nuclear import of EGFR is essential for the

anti-GBM effects of Z5. Given that KPNA2 and KPNB1 facilitates EGFR nuclear

translocation [29], we knocked KPNA2 down using a specific siRNA

(siKPNA2-1400) and confirmed a subsequent reduction in nuclear EGFR levels (Figure 6G; Supplementary Figure 3E). This intervention significantly attenuated the ability of Z5 to inhibit cell proliferation (as assessed by CCK-8 and EdU assays; Figure 6H-I, Supplementary Figure 3F) and to induce G2/M phase arrest (Figure 6J; Supplementary Figure 3G). The critical role of nuclear import was further emphasized when pharmacological inhibition of KPNB1 with importazole synergized with Z5 to further diminish its efficacy (Supplementary Figure 3F). Importantly, the partial anti-proliferative effect that remained after KPNA2 knockdown suggests that Z5's mechanism of action also involves pathways dependent on cytoplasmic and membrane-localized EGFR. This finding is also in line with our previous detection of Z5's inhibition of the EGFR-downstream mTOR and ERK pathways.

Given the limited exploration of the EGFR-WEE1 interaction in GBM, especially within clinical samples, we sought to address this gap by conducting an in-depth analysis of transcriptomic data from GBM patient cohorts. This analysis aimed to evaluate the clinical relevance of this axis and to assess the translational potential of Z5. In the CGGA database, WEE1 expression was significantly elevated in GBM compared to other glioma subtypes (Supplementary Figure 4A), with classical and mesenchymal subtypes showing higher levels than the proneural subtype (Supplementary Figure 4B). IDH-wildtype GBM exhibited stronger WEE1 expression relative to IDH-mutant tumors (Supplementary Figure 4C), consistent with a more aggressive phenotype. Survival analyses using TCGA and CGGA datasets revealed that high WEE1 expression was associated with poorer overall survival in GBM patients (Supplementary Figure 4D–F). At the protein level, immunohistochemical staining of a tissue microarray containing 64 primary GBM samples (grades 0–IV) showed a positive correlation between WEE1 intensity and

tumor grade (Supplementary Figure 4G–H). IF further confirmed colocalization of

EGFR and WEE1 in GBM tissues (Supplementary Figure 4I), supporting their

functional interaction in vivo.

To summarize, we established that EGFR acts as an upstream regulator of

WEE1 and revealed their specific nuclear interaction as a critical vulnerability. Z5

binds to EGFR, disrupts the nuclear EGFR-WEE1 complex, and consequently

inhibits downstream signaling, leading to cell cycle arrest and suppressed tumor

growth. The clinical relevance of this axis, supported by its association with

aggressive tumor subtypes and poorer patient survival, highlighting the central role

of the EGFR–WEE1 axis in GBM pathogenesis and the translational potential of Z5.

Figure 6 Z5 disrupt the nuclear EGFR-WEE1 axis. (A) Correlation between EGFR

and WEE1 expression in GBM patients. (B) SPR analysis of the interaction between

the kinase domains of EGFR and WEE1. (C) Co-IP was performed to assess

EGFR–WEE1 interaction in U87-MG cells after 15 min Z5 treatment. (D) Western

blot analysis of WEE1, p-WEE1, p-CDC2, EGFR, and p-EGFR in HEK293T cells

transfected with empty vector, WT-EGFR, or E762V-EGFR. (E) Subcellular

localization of EGFR and WEE1 in cytoplasm and nucleus was analyzed in U87-MG

cells after 15 min Z5 treatment. (F-G) IF staining of EGFR and WEE1 in NC and

siKPNA2-1400 U87-MG cells. (H) Growth curves of NC and siKPNA2-1400 GBM

cells after 48 h Z5 treatment. (I) Anti-proliferative effect of Z5 was assessed by EdU

staining in NC and siKPNA2-1400 U87-MG cells. (J) Cell cycle distribution was

analyzed by flow cytometry in NC and siKPNA2-1400 U87-MG cells after 24 h Z5

treatment.

3.7 Z5 suppresses GSCs tumorigenesis and inhibits EGFR-related signaling in

vivo

GSCs represent a distinct subpopulation within GBM, defined by their stem-like

properties and enhanced DNA repair capacity [30, 31]. Given their critical role in

treatment resistance and tumor recurrence, we chose this most challenging and

representative model to further assess Z5's anti-GBM effects. Accordingly, we

performed tumor sphere formation assay, which revealed that Z5 markedly induced

fragmentation of tumor spheres derived from the T3359 GSCs (Figure 7A–B).

Immunoblotting   further   confirmed   that   Z5   significantly   suppressed   the

EGFR–WEE1axis in these cells (Figure 7C).

For in vivo validation, we established an orthotopic xenograft model. Upon

terminal symptom onset in the first untreated (NT) mouse, one mouse per treatment

group was euthanized for histological analysis. HE staining showed that Z5 markedly

suppressed intracranial GSCs tumor growth (Figure 7D). Z5 also prolonged survival

in a dose-dependent manner. Mice in the NT group survived for a median of 102.75

days, whereas those treated with 10 mg/kg and 20 mg/kg Z5 exhibited median

survivals of 127.5 and 139 days, corresponding to 24.1% and 35.3% increases,

respectively (Figure 7E). IHC staining further demonstrated reduced EGFR and

WEE1 expression in Z5-treated tumors (Figure 7F–G). Notably, after 8 weeks of

treatment, H&E staining of heart, liver, spleen, lung, and kidney tissues revealed no

toxicity (Supplementary Figures S5A–E). These findings establish Z5 as a potent

inhibitor of GSCs growth in both in vitro and in vivo settings, accompanied by

effective suppression of EGFR-WEE1 axis and a favorable safety profile.

In conclusion, Z5 exerts potent anti-GBM efficacy via a dual mechanism: DNA

intercalation that induces damage, and targeted inhibition of EGFR at E762. The DNA

damage response is amplified by EGFR inhibition, which concurrently disrupts the

EGFR-WEE1 interaction. This disruption compromises WEE1-mediated regulation of

its downstream effector CDC2, leading to reduced p-CDC2 levels, G2/M checkpoint

failure, mitotic aberrations, and ultimately, mitotic catastrophe. Furthermore, Z5

inhibits the mTOR and ERK pathways, confirming the suppression of plasma

membrane-localized EGFR signaling as a key contributor to its efficacy. Collectively,

based on these mechanisms, Z5 demonstrates potent anti-tumor activity across diverse

preclinical GBM models, including established cell lines, patient-derived GSCs, and

orthotopic xenografts, underscoring its considerable therapeutic potential (Figure 7H).

Figure 7 Z5 suppresses GSCs tumorigenesis and inhibits EGFR-related signaling

in vivo. (A) Representative tumor sphere formation assay in T3359 cells treated with

different concentrations of Z5 for 48 h. Scale bar = 400 μm. (B) Quantitative analysis

of tumor sphere fragmentation from (A). The data are presented as the means ± SDs,

n=3, ****p < 0.0001, compared with the "0" group. (C) Expression of γ-H2AX,

WEE1, p-WEE1, PHH3, CDC2, p-CDC2, EGFR, p-EGFR, ERK, p-ERK, mTOR, and p-mTOR in T3359 cells with DMSO or Z5 treatment. (D) H&E staining of intracranial xenografts to assess tumor formation. (E) Survival analysis of mice orthotopically implanted with GSCs. The data are presented as the means $\pm$ SDs, n=4, *p < 0.05, compared with the NT group. (F) Immunohistochemical analysis of EGFR and WEE1 expression in orthotopic tumor tissues. (G) Quantification of EGFR and WEE1 levels by average optical density from five fields per mouse. The data are presented as the means $\pm$ SDs, n=3, ****p < 0.0001, compared with the NT group. (H) Schematic diagram illustrating the mechanism of Z5.

4. Discussion

Since TMZ's approval in 2005, despite extensive research over the past 2 decades, no transformative therapies have emerged. Currently, the top-priority task in this field is to spare no effort in the search for new molecules and methods that are effective against GBM. Addressing this critical gap, our study successfully identified Z5 as a novel, dual-functional EGFR inhibitor that not only demonstrates potent anti-tumor efficacy across a spectrum of preclinical GBM models but also exhibits a favorable safety profile, distinguishing it from many existing therapeutic candidates. More importantly, we have systematically elucidated its unique mechanism of action, revealing that Z5 achieves its robust effects by simultaneously inducing DNA damage through intercalation and precisely targeting the EGFR signaling axis at the E762 residue, thereby disrupting the critical EGFR-WEE1 regulatory circuit and

downstream survival pathways. This comprehensive investigation positions Z5 as a

highly promising candidate worthy of further clinical development, offering a new

strategic approach to combat this devastating disease.

We have previously established Z5 as a DNA intercalator [17]. Z5 exhibits

moderate intercalation strength compared to classical intercalators such as YOYO-1

and ethidium bromide. This property may correlate with reduced carcinogenic and

mutagenic potential, as supported by in vitro and in vivo toxicity studies in normal

cells and mouse models. Single-molecule magnetic tweezer experiments also revealed

that Z5 induces only moderate changes in DNA extension and twist under low force

conditions, which may account for its potent antitumor activity coupled with low

systemic toxicity [17]. These findings were further corroborated in the present study

through long-term toxicity assessment over 150 days in an orthotopic GBM model

using patient-derived GSCs. Given its high safety profile, further investigation into its

full range of biological effects and underlying mechanisms is warranted.

Despite the introduction of novel therapeutic modalities such as tumor-treating

fields, molecularly targeted agents, and immunotherapies, the clinical management of

GBM remains profoundly challenging. These approaches are consistently hampered

by   tumor   heterogeneity,   an   immunosuppressive   microenvironment,

and—critically—the limited penetration of the BBB, which collectively contribute to

transient responses and recurrence rates exceeding 90%[32, 33]. In particular,

conventional EGFR inhibitors (e.g., gefitinib, osimertinib) exhibit restricted efficacy

in GBM, owing not only to compensatory signaling and tumor adaptability but also to

their inadequate BBB permeability [34-36]. Z5, as a novel phenanthridine alkaloid

derivative, has shown remarkable BBB penetration and potent anti-tumor efficacy,

providing further evidence for the ability of this structural class to cross the BBB and

exert therapeutic effects in brain diseases. Consistently, natural phenanthridine

alkaloids such as narciclasine and lycorine have been confirmed by previous studies

to exhibit significant anti-GBM activity, while lycorine, galanthamine, and

haemanthamine have also demonstrated neuroprotective effects[37-39]. Of particular

note, galanthamine, a representative phenanthridine alkaloid and a natural product

from the *Amaryllidaceae* family, has been approved by the FDA for the treatment of

Alzheimer's disease [40]. Its successful clinical application serves to underscore the

potential of this chemical family to cross the BBB and treat neurological disorders,

thereby offering a compelling rationale and considerable promise for the translational

research of Z5.

DNA intercalators reversibly insert between adjacent base pairs of

double-stranded DNA, thereby altering DNA conformation, compromising structural

integrity, and interfering with DNA-processing proteins [40, 41]. Unlike alkylating

agents, which exert anticancer effects through irreversible covalent modification of

DNA, intercalators bind via noncovalent interactions—primarily van der Waals forces,

hydrogen bonding, hydrophobic effects, and/or charge-transfer interactions—resulting

in reversible DNA binding [42]. Consequently, their binding does not necessarily

induce immediate cytotoxicity. To elicit cyell-killing effects, intercalators must first

form a sufficiently stable complex with a long half-life, capable of obstructing

DNA-metabolizing enzymes and impairing essential processes such as replication,

transcription, and translation. Classic examples include anthracycline drugs like

doxorubicin and daunorubicin, which intercalate into DNA but primarily cause

cytotoxicity by inhibiting topoisomerase II, preventing DNA religation and leading to

irreversible strand breaks. In this study, we employed multiple experimental

approaches to demonstrate that beyond its DNA-intercalating activity, Z5 also

functions as a potent EGFR inhibitor. By specifically targeting the E762 residue of

EGFR, Z5 effectively suppresses canonical plasma membrane-derived signaling

pathways—such as mTOR and ERK—and concurrently impairs EGFR-mediated

DNA damage repair, resulting in the accumulation of unresolved DNA lesions.

Importantly, this strategy represents a significant advance over monotherapeutic

approaches that focus exclusively on nuclear EGFR or individual downstream

effectors[43, 44].

WEE1 plays a critical role in maintaining genomic stability by phosphorylating

CDK1/2 to enforce the G2/M checkpoint, thereby allowing DNA repair before mitotic

entry[45]. Its overexpression is frequently associated with poor prognosis and therapy

resistance in multiple cancers, while pharmacological or genetic inhibition of WEE1

can induce mitotic catastrophe in genomically unstable tumor cells[46]. In GBM,

where EGFR amplification and replication stress are highly prevalent, WEE1 serves

as a key survival factor that helps cancer cells cope with DNA damage and replication

pressure[47]. In this study, we systematically delineated, for the first time, the

functional interplay between EGFR and WEE1 in GBM. We demonstrated that Z5

disrupts this EGFR–WEE1 axis, thereby compromising the protective checkpoint

mechanism and driving GBM cells into mitotic catastrophe. These findings not only

reveal a novel mode of action for Z5 but also provide compelling evidence supporting

the EGFR–WEE1 axis as a therapeutically targetable vulnerability in GBM. Z5

represents both a mechanistic probe for understanding EGFR–WEE1 biology and a

promising therapeutic candidate worthy of further development.

While our study elucidates a novel mechanism of action for Z5, several

questions remain unresolved. First, it is still unclear whether the disruptive

effects of Z5 on the EGFR–WEE1 interaction are mediated solely through its

EGFR-targeting activity, independently of DNA intercalation, or via a combined

mechanism. Second, the structural basis of the EGFR–WEE1

interaction—particularly the precise binding interface—requires further

elucidation [7, 47, 48]. Third, it remains to be determined whether Z5 inhibits

EGFR tyrosine kinase activity and how its efficacy compares with that of existing

EGFR inhibitors. These aspects are critical for optimizing the therapeutic

application of Z5 and warrant further investigation.

5. Conclusions

In conclusion, Z5 demonstrates potent anti-GBM efficacy by concurrently targeting

DNA and EGFR, which elicits mitotic catastrophe while maintaining a favorable

safety profile. This study establishes Z5 not only as a mechanistic probe for EGFR

signaling but also as a brain-penetrant clinical candidate, and reveals disruption of the

nuclear EGFR–WEE1 axis as a novel therapeutic vulnerability in GBM. These

findings provide a strong foundation for advancing Z5 toward clinical translation and

offer a promising new strategy for GBM treatment.

6. Abbreviations

Abbreviation	Full term
GBM	Glioblastoma
EGFR	Epidermal growth factor receptor
Z5	ZYH005
GSCs	glioblastoma stem cells
qPCR	Quantitative polymerase chain reaction
γ-H2AX	Phospho-Histone H2A.X
TMZ	Temozolomide
DNA-PKcs	DNA-dependent protein kinase catalytic subunit
NHEJ	nonhomologous end joining
DDR	DNA damage response
TKIs	Tyrosine kinase inhibitors
BBB	Blood–brain barrier
GSCs	Glioblastoma stem cells
FBS	Fetal bovine serum
CTR	Control
SOPs	Standard operating procedures
STR	Short tandem repeat
GSEA	Gene Set Enrichment Analysis
LiP-MS	Limited Proteolysis–Mass Spectrometry
IHC	Immunohistochemistry
TMA	Tissue Microarray
CETSA	Cellular thermal shift assay
DARTS	Drug affinity responsive target stability

SPR	Surface plasmon resonance
GO	Gene Ontology
PHH3	Phospho-Histone H3
H&E	Hematoxylin and eosin
CGGA	Chinese Glioma Genome Atlas
IDH	Isocitrate Dehydrogenase
TCGA	The Cancer Genome Atlas
OS	Overall survival
Co-IP	Co-Immunoprecipitation
NT	Untreated
KEGG	Kyoto Encyclopedia of Genes and Genomes

7. Declarations

7.1 Ethics approval and consent to participate

GSC cells were obtained from glioma patients who underwent surgery at the Department of Neurosurgery of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. All participants provided written informed consent, and the study was approved by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (Serial number: 2021-lEC-A244). The Animal Experiment Administration Committee of the Huazhong University of Science and Technology (HUST) approved all the animal experiments to ensure ethical and humane treatment of the animals (IACUC number: 3028).

7.2 Consent for publication

Not applicable.

7.3 Availability of data and materials

This study did not generate new reagents or original code. All the data generated or analyzed during this study are included in this article and its supplementary information files. Microarray data can be accessed through the following link: https://doi.org/10.1101/2025.04.14.25325787

7.4 Competing interests

The authors declare that they have no conflicts of interest.

7.5 Funding

This work was financially supported by the National Natural Science Foundation of China [grant number 82073886], the Program for Medical Youth Talent of Hubei Province (2024--2027), the Hubei Provincial Administration of Traditional Chinese Medicine Research Fund [grant number ZY2023M063], the National Key R&D Program of China [grant number 2021YFA0910500] and the National Natural Science Foundation of China [grant numbers 82473132 and 82072805].

7.6 Author contributions

Yonghui Zhang, Qingyi Tong, Suojun Zhang and Xingjiang Yu: Funding acquisition, Resources. Jianzheng Huang and Qingyi Tong: Data curation, writing-original draft and writing-review editing. Zijun Zhang, Xiao Yang and Ziming Zhao: Validation. Zengwei Luo, Junjun Liu, Suitian Lai: Visualization. Chao Song and Shouchang Feng: Resources.

7.7 Acknowledgments

We thank Dr. Shideng Bao, Dr. Jeremy Rich and Professor Xingjiang Yu for generously providing GSCs (T3359 and D456). We thank the Medical Subcenter of HUST Analytical & Testing Center for acquiring the data and the Experimental Animal Centre of HUST for providing the animal experimentation facilities.

8. References

[1] M. Weller, P.Y. Wen, S.M. Chang, L. Dirven, M. Lim, M. Monje, G. Reifenberger, Glioma, Nature Reviews Disease Primers, 10 (2024) 33.

[2] S. Grochans, A.M. Cybulska, D. Siminska, J. Korbecki, K. Kojder, D. Chlubek, I. Baranowska-Bosiacka, Epidemiology of Glioblastoma Multiforme-Literature Review, Cancers (Basel), 14 (2022).

[3] W.J.J. Alick P, A Review of Glioblastoma and Other Primary Brain Malignancies, 330 (2023).

[4] S.M.B. Rodriguez, A. Kamel, G.V. Ciubotaru, G. Onose, A.S. Sevastre, V. Sfredel, S. Danoiu, A. Dricu, L.G. Tataranu, An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma, Int J Mol Sci, 24 (2023).

[5] G. Liccardi, J.A. Hartley, D. Hochhauser, EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment, Cancer Res, 71 (2011) 1103-1114.

[6] B. Lin, J. Ziebro, E. Smithberger, K.R. Skinner, E. Zhao, T.F. Cloughesy, Z.A. Binder, D.M. O'Rourke, D.A. Nathanson, F.B. Furnari, C.R. Miller, EGFR, the Lazarus target for precision oncology in glioblastoma, Neuro Oncol, 24 (2022) 2035-2062.

[7] Z. Zhou, H. Lu, S. Zhu, A. Gomaa, Z. Chen, J. Yan, K. Washington, W. El-Rifai, C. Dang, D. Peng, Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage, J Exp Clin Cancer Res, 38 (2019) 13.

[8] R.E. Meyn, A. Munshi, J.V. Haymach, L. Milas, K.K. Ang, Receptor signaling as a regulatory mechanism of DNA repair, Radiother Oncol, 92 (2009) 316-322.

[9] M. Rajput, R. Singh, N. Singh, R.P. Singh, EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways, Life Sci, 286 (2021) 120031.

[10] M. Prewett, D.S. Deevi, R. Bassi, F. Fan, L.M. Ellis, D.J. Hicklin, J.R. Tonra, Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab, Clin Cancer Res, 13 (2007) 7432-7440.

[11] G. Kim, Y.T. Ko, Small molecule tyrosine kinase inhibitors in glioblastoma, Arch Pharm Res, 43 (2020) 385-394.

[12] Z. Chen, K.A. Vallega, D. Wang, Z. Quan, S. Fan, Q. Wang, T. Leal, S.S. Ramalingam, S.Y. Sun, DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models, J Clin Invest, 134 (2024).

[13] M.J. Lee, A.S. Ye, A.K. Gardino, A.M. Heijink, P.K. Sorger, G. MacBeath, M.B. Yaffe, Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks, Cell, 149 (2012) 780-794.

[14] Z. Sharifi, B. Abdulkarim, B. Meehan, J. Rak, P. Daniel, J. Schmitt, N. Lauzon, K. Eppert, H.M.

Duncan, K. Petrecca, M.-C. Guiot, B. Jean-Claude, S. Sabri, Mechanisms and Antitumor Activity of a Binary EGFR/DNA–Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide, Clinical Cancer Research, 25 (2019) 7594-7608.

[15] Z. Jin, G. Yao, Amaryllidaceae and Sceletium alkaloids, Natural Product Reports, (2019).

[16] I. Azad, R. Ahmad, T. Khan, M. Saquib, F. Hassan, Y. Akhter, A.R. Khan, M. Nasibullah, Phenanthridine derivatives as promising new anticancer agents: synthesis, biological evaluation and binding studies, Future medicinal chemistry, 12 (2020) 709-739.

[17] Q. Tong, H. You, X. Chen, K. Wang, W. Sun, Y. Pei, X. Zhao, M. Yuan, H. Zhu, Z. Luo, Y. Zhang, ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia, Nucleic Acids Res, 46 (2018) 3284-3297.

[18] G. Van Goietsenoven, V. Mathieu, F. Lefranc, A. Kornienko, A. Evidente, R. Kiss, Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers, Med Res Rev, 33 (2013) 439-455.

[19] F.L. Laurent Ingrassia, Janique Dewelle, Laurent Pottier, Ve´ronique Mathieu, Sabine Spiegl-Kreinecker, Se´bastien Sauvage, Mohamed El Yazidi, Mischae¨l Dehoux, Walter Berger, Eric Van Quaquebeke, and Robert Kiss, Structure-Activity Relationship Analysis of Novel Derivatives of Narciclasine (an Amaryllidaceae Isocarbostyril Derivative) as Potential Anticancer Agents, Journal of Medicinal Chemistry, 52 (2009) 1100-1114.

[20] R.J.P.m. Fürst, Narciclasine – an amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties, Planta medica, 82 (2016) 1389-1394.

[21] J. Shen, T. Zhang, Z. Cheng, N. Zhu, H. Wang, L. Lin, Z. Wang, H. Yi, M. Hu, Lycorine inhibits glioblastoma multiforme growth through EGFR suppression, J Exp Clin Cancer Res, 37 (2018) 157.

[22] Y. Yuan, X. He, X. Li, Y. Liu, Y. Tang, H. Deng, X. Shi, Narciclasine induces autophagy-mediated apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway, BMC Pharmacol Toxicol, 22 (2021) 70.

[23] D. Liu, H. Zhu, L. Cheng, R. Li, X. Ma, J. Wang, J. Wang, S. Zhang, Y. Li, K. Shu, X. Yu, C. Li, Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation, Neuro Oncol, 26 (2024) 872-888.

[24] T.S. Beyett, J.K. Rana, I.K. Schaeffner, D.E. Heppner, M.J. Eck, Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase, ChemMedChem, 19 (2024) e202300343.

[25] S. Unni, Y. Huang, R.M. Hanson, M. Tobias, S. Krishnan, W.W. Li, J.E. Nielsen, N.A. Baker, Web servers and services for electrostatics calculations with APBS and PDB2PQR, J Comput Chem, 32 (2011) 1488-1491.

[26] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J Comput Chem, 30 (2009) 2785-2791.

[27] L. Malinovska, V. Cappelletti, D. Kohler, I. Piazza, T.H. Tsai, M. Pepelnjak, P. Stalder, C. Dorig, F. Sesterhenn, F. Elsasser, L. Kralickova, N. Beaton, L. Reiter, N. de Souza, O. Vitek, P. Picotti, Proteome-wide structural changes measured with limited proteolysis-mass spectrometry: an advanced protocol for high-throughput applications, Nat Protoc, 18 (2023) 659-682.

[28] Y. Hu, Z. Zhang, W. Ye, W. Zhang, M. Hu, W. Yuan, H. Wang, X. Xiao, T. Wu, A DNA
structure-mediated fluorescent biosensor for apurinic/apyrimidinic endonuclease 1 activity detection
with ultra-high sensitivity and selectivity, Sensors and Actuators B: Chemical, 330 (2021).

[29] D.J. Chen, C.S. Nirodi, The epidermal growth factor receptor: a role in repair of radiation-induced
DNA damage, Clin Cancer Res, 13 (2007) 6555-6560.

[30] Gimple RC, Bhargava S, Dixit D, R. JN, Glioblastoma stem cells: lessons from the tumor
hierarchy in a lethal cancer, Genes Dev, 33(11-12) (2019) 591-609.

[31] M.L. Suva, I. Tirosh, The Glioma Stem Cell Model in the Era of Single-Cell Genomics, Cancer
Cell, 37 (2020) 630-636.

[32] Y. Liu, F. Zhou, H. Ali, J.D. Lathia, P. Chen, Immunotherapy for glioblastoma: current state,
challenges, and future perspectives, Cellular & Molecular Immunology, 21 (2024) 1354-1375.

[33] M.E. Davis, Glioblastoma: Overview of Disease and Treatment, Clinical journal of oncology
nursing, 20 (2016) S2-8.

[34] X.-P. Li, Z.-Q. Guo, B.-F. Wang, M. Zhao, EGFR alterations in glioblastoma play a role in
antitumor immunity reg ulation, Front. Oncol., 13.

[35] A. Lee, M. Arasaratnam, D.L.H. Chan, M. Khasraw, V.M. Howell, H. Wheeler, Anti-epidermal
growth factor receptor therapy for glioblastoma in adults, The Cochrane database of systematic reviews,
5 (2020) Cd013238.

[36] M. Westphal, C.L. Maire, K. Lamszus, EGFR as a Target for Glioblastoma Treatment: An
Unfulfilled Promise, CNS Drugs, 31 (2017) 723-735.

[37] N. Cortes, R.A. Posada-Duque, R. Alvarez, F. Alzate, S. Berkov, G.P. Cardona-Gómez, E. Osorio,

Neuroprotective activity and acetylcholinesterase inhibition of five Amaryllidaceae species: A
comparative study, Life Sciences, 122 (2015) 42-50.

[38] E. Kohelová, J. Maříková, J. Korábečný, D. Hulcová, T. Kučera, D. Jun, J. Chlebek, J. Jenčo, M.

Šafratová, M. Hrabinová, A. Ritomská, M. Malaník, R. Peřinová, K. Breiterová, J. Kuneš, L. Nová

ková, L. Opletal, L. Cahlíková, Alkaloids of Zephyranthes citrina (Amaryllidaceae) and their

implication to Alzheimer's disease: Isolation, structural elucidation and biological activity, Bioorganic
Chemistry, 107 (2021).

[39] Q. Zhu, X.-x. Zhuang, J.-y. Chen, N.-n. Yuan, Y. Chen, C.-z. Cai, J.-q. Tan, H.-x. Su, J.-h. Lu,
Lycorine, a natural alkaloid, promotes the degradation of alpha-synuclein via PKA-mediated UPS
activation in transgenic Parkinson's disease models, Phytomedicine, 87 (2021).

[40] S. Venugopal, V. Sharma, A. Mehra, I. Singh, G. Singh, DNA intercalators as anticancer agents,
Chem Biol Drug Des, 100 (2022) 580-598.

[41] A.S. Biebricher, I. Heller, R.F.H. Roijmans, T.P. Hoekstra, E.J.G. Peterman, G.J.L. Wuite, The
impact of DNA intercalators on DNA and DNA-processing enzymes elucidated through
force-dependent binding kinetics, Nature communications, 6 (2015) 7304.

[42] R. Martinez, L. Chacón-García., The search of DNA-intercalators as antitumoral drugs: what it

worked and what did not work, Current Medicinal Chemistry, 12 (2005) 127-151.

[43] H.W. Lo, M.C. Hung, Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell

cycle progression, nitric oxide pathway and patient survival, Br J Cancer, 94 (2006) 184-188.

[44] T.M. Brand, M. Iida, N. Luthar, M.M. Starr, E.J. Huppert, D.L. Wheeler, Nuclear EGFR as a molecular target in cancer, Radiother Oncol, 108 (2013) 370-377.

[45] A. Ghelli Luserna di Rora, C. Cerchione, G. Martinelli, G. Simonetti, A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target, J Hematol Oncol, 13 (2020) 126.

[46] K. Thangaretnam, M.O. Islam, J. Lv, A. El-Rifai, A. Perloff, H.L. Soutto, D. Peng, Z. Chen, WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials, Crit Rev Oncol Hematol, 211 (2025) 104710.

[47] M.H. Cetin, T. Rieckmann, K. Hoffer, B. Riepen, S. Christiansen, F. Gatzemeier, S. Feyerabend, M. Schoof, U. Schuller, C. Petersen, M. Mynarek, K. Rothkamm, M. Kriegs, N. Struve, G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells, Radiat Oncol, 18 (2023) 19.

[48] Y. Volman, R. Hefetz, E. Galun, J. Rachmilewitz, DNA damage alters EGFR signaling and reprograms cellular response via Mre-11, Sci Rep, 12 (2022) 5760.

Supporting Information

1. Materials and Methods

1.1 Histology analysis

Brain tissues were fixed with 4% paraformaldehyde for 12 hours and embedded in paraffin. The paraffin-embedded brain specimens were sectioned and stained with H&E, according to the manufacturer's protocol. Other sections of brain specimens were subjected to immunohistochemistry (IHC), and the samples were incubated with primary antibodies against WEE1 (Cell Signaling Technology) and EGFR (Abclonal) for 30 minutes at room temperature. Subsequently, the slides were incubated with secondary antibodies and hematoxylin.

1.2 Determination of Blood-Brain Barrier (BBB) Penetration:

To evaluate the BBB penetration of Z5, twelve C57BL/6 mice were randomly divided into four groups: a vehicle control group and three treatment groups sacrificed at 0.25, 0.5, and 2 h after intraperitoneal administration of Z5. After injection, mice were anesthetized with isoflurane and blood samples (~0.5 mL) were collected by cardiac puncture into pre-chilled tubes containing EDTA-K□ as an anticoagulant. Samples were kept on wet ice and centrifuged within 1 h of collection (1700 × g, 4□°C, 10 min) to obtain plasma.

Subsequently, mice were transcardially perfused with ice-cold saline (0.9% NaCl) until the liver appeared pale to remove intravascular blood. Brain tissues were then harvested and homogenized in a ratio of 1:3 (w/v; 1 g tissue to 3 mL water). The concentrations of Z5 in plasma and brain homogenate were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).

1.3 Cell viability assay

Cell viability was measured using the CCK-8 assay. Briefly, cells were seeded into

96-well plates at a density of 3,000 cells per well and allowed to adhere overnight

before treatment with various concentrations of drugs or vehicle. At 24, 48, or 72 h

post-treatment, 10 μL of CCK-8 reagent was added to each well and cells were

incubated at 37°C for 4 h. The optical density (OD) was measured at 450 nm using a

microplate reader. IC□□ values were determined by nonlinear regression analysis of

dose-response curves using SPSS software

For drug combination studies, cells were co-treated with varying concentrations of

ZYH005 and importazole for 48 h. Synergy scores were calculated using the

SynergyFinder+ web application: SynergyFinder+.

1.4 Clone formation assay

853 Cells were seeded into 6-well plates at a density of 500 cells per well and allowed to

854 adhere overnight. Cells were then treated with DMSO or Z5 for 12 h, after which the

855 drug-containing medium was replaced with fresh drug-free medium. The medium was

856 changed every three days thereafter. The cells were collected after 14 days of culture.

1.5 EdU staining

858 EdU cell proliferation staining was performed using an EdU kit (BeyoClick™ EdU

859 Cell Proliferation Kit with Alexa Fluor 488, Beyotime, China). The kit was used

860 according to the manufacturer's instructions.

1.6 Immunoblotting assay

Immunoblotting was performed as previously published[1]. The membranes were

washed with TBST and incubated with the secondary antibodies anti-rabbit IgG (H+L)

(CST, #5151, Boston, American) and anti-mouse IgG (H+L) (CST, #5257, Boston,

American), followed by imaging using a Li-Cor Odyssey scanner (LI-COR, USA).

Image analysis was executed using Image Studio software. Primary antibodies used in

the study are listed in **Supplementary Table S2**.

1.7 DNA fragment detection assay

Cells were seeded into 6-well plates and incubated with DMSO or Z5. After 24 hours,

the cells were washed once with cold PBS. Genomic DNA was extracted using the

Universal Genomic DNA Purification Mini Spin Kit, as per the manufacturer's

instructions. DNA fragment detection was performed as previously published

[3]. Briefly, a mixture of DNA, TdT, and dATP was prepared and incubated at 37□

for 30 minutes, followed by an additional incubation at 75□ for 20 minutes. Finally,

Endo IV and the probe were added to the system. The fluorescence intensity was

measured immediately using the real-time PCR instrument (RRID: SCR_018018).

1.8 Cellular Thermal Shift Assay (CETSA)

After freeze-thawing the GBM cells twice using liquid nitrogen to get the whole

protein, divide the protein solution into two equal parts. Incubate each part with

DMSO or Z5 at room temperature for 1 hour. After incubation, aliquot the protein

solution and incubate at different temperatures for three minutes. Following this,

centrifuge the samples at 12000g, collect the supernatants, and perform

immunoblotting analysis.

1.9 Drug Affinity Responsive Target Stability Assay (DARTS)

DARTS was performed as previously published[2]. Briefly, after lysing GBM cells with

RIPA buffer, divide the protein solution into five equal parts, with each portion being

90 μL. Measure the protein concentration using the BCA kit. Meanwhile, incubate

each portion of the protein solution with DMSO or different concentrations of Z5 at

room temperature for 15 minutes. Based on the protein concentration, add protease

solution at a ratio of 1:700 (enzyme: protein) and incubate at room temperature for 10

minutes. Subsequently, stop the reaction by adding a protease inhibitor cocktail and

SDS-PAGE loading buffer followed by immunoblotting.

1.10 Surface plasmon resonance (SPR)

A Biacore 1K instrument was used to measure the binding kinetics of the human

EGFR kinase domain (EGFR residues 704-1016) and human WEE1 kinase domain

(WEE1 residues 293-568) to Z5. Measurements were performed at 25□. Proteins

were dissolved in PBS, pH7.4. The proteins were immobilized on the CM5 sensor

chip (Cytiva, 29149603, Shanghai, China) using the amine-coupling method

according to standard protocols. Data were processed using standard

double-referencing and fit to a 1:1 binding model using Biacore 1K Evaluation

software. The association rate (K_{on}, $M^{-1}□s^{-1}$), dissociation rate (K_{off}, s^{-1}), estimate of

error (SE), Chi-Square (Chi^2), and statistic and maximum response (R_{max}) and

response units (RU) were determined. The equilibrium dissociation constant (K_d) was

calculated from the relationship $K_D□=□K_{off}/K_{on}$ (M). GraphPad Prism 9.0 was used

for image processing.

1.11 Transfection of siRNA and plasmids

U87-MG and U251-MG cell lines were transfected with siRNA using siRNA-Mate

(GenePharma, Suzhou, China). Transfections were carried out following the

siRNA-Mate protocol. The siRNA sequences were shown in **Supplementary Table**

S3. The pcdna3.1 (Vehicle), EGFR WT and EGFR E762V plasmids were purchased

from Gene Create (Wuhan, China). The plasmids were transfected into the HEK293T

cells using Lipofectamine 3000 (Thermo Scientific, USA) according to the

manufacturer's instructions. The plasmid sequences were shown in **Supplementary**

Table S4.

1.12 Limited Proteolysis–Mass Spectrometry (LiP-MS)

Recombinant EGFR-kinase domain (EGFR residues 704-1016) were incubated with

100 μM of Z5 at 25°C for 15 minutes; Control Group: Recombinant EGFR-kinase

domain were incubated with an equal volume of DMSO at 25°C for 15 minutes. After

incubation, Proteinase K was added to the protein solutions (enzyme-to-protein ratio

by weight is 1:100), and the mixture is digested at 25°C for 3 minutes, followed by

immediate heat treatment at 98°C for 5 minutes to stop the enzymatic reaction. The

samples, post-Proteinase K digestion, were cooled to room temperature, then an equal

volume of 2% SDC (prepared in 20 mM Tris-HCl buffer) is added, adjusting pH to

7-8.5 with ammonium bicarbonate. The samples were heated at 98°C for 5 minutes,

cooled to room temperature, and then 5 μL of 0.1 M TCEP and 5 μL of 0.4 M

chloroacetamide were added, reacting in the dark at 45°C with shaking at 1500 rpm

for 5 minutes. After cooling the samples to room temperature, trypsin (Promega,

Madison, WI) was added at an enzyme-to-sample ratio (by weight) of 1:50 and

incubated overnight at 37°C for proteolysis. An appropriate amount of formic acid

was added to achieve a final concentration of 1.5%, mixed thoroughly, and

centrifuged at 16000g for 5 minutes. The supernatant was collected, desalted using a

C18 desalting column, and dried under vacuum. Each sample had been resuspended in

30 μL of Solvent A (A: 0.1% formic acid in water) to create a suspension. Then, 9 μL

of the suspension was mixed with 1 μL of 10× iRT peptide mix. After mixing

thoroughly, the samples were subjected to separation by nano-Liquid Chromatography

(nano-LC). The separated peptides were analyzed by online electrospray tandem mass

spectrometry (MS/MS). The differential peptides identified by LIP-MS can be found

in **Supplementary Table S5**.

1.13 qPCR

Total RNA was extracted from cells with Trizol and was transcribed to cDNA using

HiScript QRT SuperMix reverse transcriptase (Vazyme, R223–01, Nanjing, China).

qPCR was then performed on ABI QuantStudio 5 (Thermo Fisher Scientific, USA,

RRID: SCR_018018) using SYBR Green qPCR Mix (Vazyme Biotech Co.,Ltd,

China). Relative mRNA levels were normalized to GAPDH. Primer sequences were

listed in **Supplementary Table S6**.

1.14 Cell cycle detection assay

Following drug treatment, cells were harvested by centrifugation at $300 \times g$ for 5 min,

and the supernatant was carefully removed. The cell pellet was resuspended in

phosphate-buffered saline (PBS) and re-centrifuged under the same conditions to

wash. Subsequently, cells were fixed by slow addition of ice-cold 70% ethanol while

vortexing, and stored at 4 °C overnight.

On the following day, fixed cells were pelleted by centrifugation and washed once

with PBS. For combined phospho-histone H3 (PHH3) and propidium iodide (PI)

staining, cells were first incubated with primary anti-PHH3 antibody at room

temperature for 1 hour with gentle agitation. Following three washes with PBS, cells

were incubated with Alexa Fluor® 488-conjugated anti-mouse IgG secondary

antibody (dilution 1:200) in the dark at 4□°C for 1 hour. After three additional PBS

washes, cells were resuspended in staining buffer containing 0.05% Triton X-100,

50□µg/mL PI, and 100□µg/mL RNase A, and incubated at 37□°C for 30 minutes in

the dark. Finally, cells were washed three times with PBS before analysis using a flow

cytometer.

For PI single staining, an identical procedure was followed, omitting the PHH3

antibody and secondary antibody incubations. Instead, cells were directly subjected to

permeabilization and staining with PI/RNase solution under the same conditions as

described above.

1.15 Immunofluorescence assay

Immunofluorescence analysis was performed as previously published[4]. All images

were captured using a confocal laser scanning microscope (Nikon AX/AX R with

NSPARC, Japan). The primary antibodies used are listed in **Supplementary Table S2.**

For GBM cell lines, secondary antibodies were anti-rabbit IgH (H+L) (Alexa Fluor

647 Conjugate) (RRID：AB_10693544) and anti-mouse IgH (H+L) (Alexa Fluor 488

Conjugate) (RRID: AB_10694704). For GBM patient tissue, secondary antibodies

were anti-rabbit IgH (H+L) (Alexa Fluor 488 Conjugate) (RRID：AB_1904025) and

anti-mouse IgH (H+L) (Alexa Fluor 488 Conjugate) (RRID: AB_1904023).

1.16 Co-Immunoprecipitation assay

U87-MG and U251-MG cells were treated with Z5 for 15 min, followed by lysis in

RIPA buffer containing protease and phosphatase inhibitors. Lysates were incubated

on ice for 15 min and cleared by centrifugation (12,000 × g, 10 min, 4 °C). An

aliquot of each lysate was reserved as whole-cell lysate (WCL) input. The remaining

lysate was incubated with anti-EGFR antibody (Santa Cruz Biotechnology) at 4 °C

for 1 h with rotation. Pre-washed Protein A/G PLUS-Agarose beads (Santa Cruz

Biotechnology) were then added, and the mixture was incubated overnight at 4 °C.

The beads were washed three times with ice-cold RIPA buffer, resuspended in 1× SDS

loading buffer, and boiled at 95 °C for 10 min to elute bound proteins. Samples were

analyzed by SDS-PAGE and immunoblotting with specific antibodies.

1.17 Clinical Bioinformatics Analysis of WEE1

Bioinformatic analyses of WEE1 expression and its correlation with patient survival

in GBM were conducted using data from the Gliovis database.

2. Supplementary Figures and Legends

Supplementary Figure 1 Structure and permeability of Z5. (A) Chemical structure

of Z5. (B) Detection of intracranial drug concentrations at different time points after

intraperitoneal injection of Z5 using LC-MS/MS (n=3). (C) Detection of plasma drug

concentrations at different time points after intraperitoneal injection of Z5 using

LC-MS/MS (n=3). (D) Ratio of intracranial drug concentration to plasma drug

concentration at different time points after intraperitoneal injection of Z5 (n=3).

Supplementary Figure 2 Microarray data and GSEA analysis of Z5 treated GBM

cells. (A) Heatmap of microarray data from U87-MG cells treated with DMSO or Z5.

(B) Volcano plot showing differentially expressed genes in U87-MG cells after Z5

treatment (|log☐ fold change| > 1, adjusted $p < 0.05$). (C) qPCR validation of selected

differentially expressed genes in GBM cell lines. (D) GSEA analysis of base excision

repair, mismatch repair, nucleotide excision repair and homologous recombination

pathways. (E) GSEA analysis of mitotic spindle pathways.

1006

Supplementary Figure 3 Z5 disrupt the nuclear EGFR-WEE1 axis. (A) Co-IP

analysis of EGFR–WEE1 interaction in U251-MG cells after 15 min DMSO or Z5

treatment in U251-MG cells. (B-C) Immunoblot analysis of WEE1, p-WEE1, CDC2,

p-CDC2, EGFR, p-EGFR, ERK, p-ERK, mTOR, and p-mTOR in U87-MG cells

following WEE1 or EGFR knockdown, or treatment with MK1775 (4 μM) and

AZD9291 (8 μM). (D)Immunofluorescence (IF) staining was used to analyze the

localization of EGFR and WEE1 in U251-MG cells. (E) Efficiency of KPNA2

silencing by siRNA transfection was assessed via immunoblot. (F) Anti-proliferative

effect of Z5 in NC and si-KPNA2 GBM cells was evaluated by EdU staining. (G) Cell

cycle distribution in NC and si-KPNA2 U251-MG cells was analyzed by flow

cytometry after 24 h Z5 treatment. (H)ZIP synergy score analysis of the combinatorial

effect between Z5 and the KPNB1 inhibitor importazole.

Supplementary Figure 4 WEE1 expression correlates with poor survival and EGFR levels. (A) WEE1 expression across glioma subtypes in the CGGA cohort. (B) WEE1 expression across GBM subtypes in the CGGA database. (C) WEE1 expression in IDH-mutant and IDH-wildtype GBM. Survival analysis based on WEE1 expression in (D) glioma patients (CGGA), (E) GBM/LGG patients (TCGA), and (F) GBM patients (CGGA). (G) Tissue microarray (TMA) of GBM samples. (H) Representative images of WEE1 immunohistochemistry on the TMA are shown (original magnification: upper: 5x; lower: 40x). (I) IF staining images of tumor tissues from GBM patients.

1030

1031 **Supplementary Figure 5 Histological Evaluation of Organ Toxicity by Z5 Using**

1032 **H&E Staining.** (A) H&E-stained sections of the heart. (B) H&E-stained sections of

1033 the liver. (C) H&E-stained sections of the spleen. (D) H&E-stained sections of the

1034 lung. (E) H&E-stained sections of the kidney.

1035

1036

1037 **Supplementary Figure S6** Complete membrane images of immunoblotting results

1038 shown in Fig. 1E, 2A, 2B, 2D and 3D.

1039

1040

1041   **Supplementary Figure S7** Complete membrane images of immunoblotting results

1042   shown in Fig. 4E, 5F, 6C and Supplementary Fig.3A.

1043

1044

1045 **Supplementary Figure S8** Complete membrane images of immunoblotting results

1046 shown in Fig.6D and Supplementary Fig. 3B, 3C.

1047

Fig.6E

Supplementary Fig.3E

Fig7C

1049 **Supplementary Figure S9** Complete membrane images of immunoblotting results

1050 shown in Fig. 6E, 7C and Supplementary Fig. 3E.

1051

3. References

1. S H. Western Blot Analysis. *Nanotoxicity: Methods in Molecular Biology.* 2012; 926:87-97.

2. Pai MY, Lomenick B, Hwang H, et al. Drug affinity responsive target stability (DARTS) for
small-molecule target identification. *Methods Mol Biol.* 2015; 1263:287-298.

3. Hu Y, Zhang Z, Ye W, et al. A DNA structure-mediated fluorescent biosensor for
apurinic/apyrimidinic endonuclease 1 activity detection with ultra-high sensitivity and
selectivity. *Sensors and Actuators B: Chemical.* 2021; 330.

4. Im K, Mareninov S, Diaz MFP, Yong WH. An Introduction to Performing
Immunofluorescence Staining. *Methods Mol Biol.* 2019; 1897:299-311.

1061